At Goodwin, Ms. Grammel has been a member of four federal jury and bench trial teams and has worked on appellate matters in the First Circuit and the Supreme Judicial Court of Massachusetts.
Representative matters include:
- Reckitt Benckiser Pharmaceuticals Inc. et al. v. Dr. Reddy’s Laboratories, S.A. et al., No. 14-1451-RGA (D. Del.). Representing Dr. Reddy’s in Hatch-Waxman suit regarding Dr. Reddy’s proposed generic versions of SUBOXONE® (buprenorphine/naloxone) sublingual films, resulting in trial judgment of non-infringement of all asserted claims. Asserted patents included formulation and process claims.
- Tris Pharma, Inc. v. Actavis Laboratories FL, Inc., No. 1:14-cv-01309-GMS (D. Del.). Representing Actavis in Hatch-Waxman suit regarding Actavis’s proposed generic version of QUILLIVANT® (methylphenidate), resulting in trial judgment of invalidity of all asserted claims. Asserted patents included pharmacokinetic and formulation claims.
- AstraZeneca Pharmaceuticals LP et al. v. Teva Pharmaceuticals USA, Inc., No. 14-1478-GMS (D. Del.). Representing Teva in Hatch-Waxman suit regarding Teva’s proposed generic version of BYETTA® (exenatide), resulting in settlement of all claims following a favorable decision on claim construction. Asserted patents included formulation and method of treatment claims.
- Veracode, Inc. et al v. Appthority, Inc., No. 12-10487-DPW (D. Mass.). Representing patent owner in infringement suit against a competitor asserting patents relating to analysis and review of source code, resulting in jury verdict and post-trial judgment as a matter of law of willful infringement and entry of a permanent injunction.
In addition to her IP work, Ms. Grammel completed a six-month rotation with the Middlesex County District Attorney’s Office, during which she first chaired 15 trials and over a dozen evidentiary hearings and argued countless non-evidentiary legal issues before the Court. Ms. Grammel was also one of the Goodwin attorneys on the trial team that defended former SAC Capital Advisors portfolio manager Mathew Martoma. In the largest-ever insider trading prosecution brought to trial, Mr. Martoma faced charges that he improperly obtained non-public information about the results of a high-profile pharmaceutical clinical trial and used this information to make trades resulting in profit and avoided losses of over $275 million.
Ms. Grammel is a member of the Boston Bar Association, the American Bar Association and the National Association of Women Lawyers.